Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Canada's biggest provinces seek clampdown on social gatherings as coronavirus cases top 150,000

share with twitter share with LinkedIn share with facebook
09/25/2020 | 05:17pm EDT
Canada's Prime Minister Justin Trudeau takes part in a news conference on Parliament Hill in Ottawa

Canada's two most populous provinces on Friday moved to clamp down further on social gatherings in a bid to slow a second wave of coronavirus infections that since the start of the pandemic now total more than 150,000 nationwide.

Ontario ordered the closure of bars and restaurants from midnight to 5 a.m. except for takeout and delivery and said strip clubs would have to shut down from Saturday.

Premier Doug Ford, whose government has already slashed the size of permitted gatherings indoor and outdoors, repeated his concerns that the majority of new cases were in people under 40.

"I can tell you I don't see seniors going into nightclubs too often," he told a daily briefing.

Health officials in Canada have been making increasingly gloomy comments in recent days. Theresa Tam, the chief medical officer, told reporters on Friday that some local authorities could be overwhelmed unless the wave was curbed.

"We now have active cases in every single province. What we do now will be critical for the weeks and months to come," Prime Minister Justin Trudeau told the same event.

In Quebec, Health Minister Christian Dube urged residents to cut down on social interactions.

"We're asking you to make a special effort for the next 28 days," he told a news conference, saying the government did not want to close bars because people might then attend private parties that are harder to control.

Ontario and Quebec together account for 79% of the 150,140 cases reported in Canada so far and 93% of the 9,249 deaths.

Trudeau said Canada signed a deal with AstraZeneca PLC to buy up to 20 million doses of its COVID-19 vaccine candidate. It is among the leading candidates in the global race for a vaccine.

Canada has now signed deals for a total of around 300 million doses of vaccine candidates from a number of major pharmaceutical firms.

By Mahad Arale and Allison Lampert

share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:44pPfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a..
12:34pEuropean cities plead for more flu shots as winter looms, pandemic rages
12:23pLondon stocks end higher, fresh stimulus helps
09:52aGLOBAL MARKETS LIVE : The Coca-Cola Company, L'Oréal, AT&T...
05:45aCovid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
12:20aBritain partners with Oxford firm to assess coronavirus vaccine T cell respon..
10/21ASTRAZENECA : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in ..
10/21ASTRAZENECA : Operation Warp Speed Chief Slaoui Expects U.S. Trials Of Vaccines ..
10/21Ecuador signs COVID-19 vaccine supply deals with pharma companies
10/21ASTRAZENECA : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in ..
More news
Financials (USD)
Sales 2020 26 717 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 172 M - -
P/E ratio 2020 47,6x
Yield 2020 2,71%
Capitalization 136 B 137 B -
EV / Sales 2020 5,60x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,20 $
Last Close Price 103,98 $
Spread / Highest target 49,5%
Spread / Average Target 13,7%
Spread / Lowest Target -36,5%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.33%378 942
ROCHE HOLDING AG-4.73%283 006
PFIZER INC.-4.31%206 049
MERCK & CO., INC.-14.16%197 458
NOVARTIS AG-16.89%186 106